
SUPPORTING ONCOLOGY PATIENT OUTCOMES THROUGH TARGETED NUTRITIONAL INTERVENTION WITH OMEGA-3 FATTY ACIDS




Cancer cachexia cannot be fully reversed by conventional nutritional support². Addressing malnutrition and inflammation through tailored nutritional support can improve the overall health and clinical outcomes of patients with cancer¹⁻³.

THE ANTI-INFLAMMATORY ROLE OF OMEGA-3 FATTY ACIDS

Omega-3 poly-unsaturated fatty acids (PUFAs; Eicosapentaenoic acid (EPA) and docosahexaenoic (DHA)) are known for their **anti-inflammatory properties**^{11,12}.

ESPEN* GUIDELINES RECOMMEND OMEGA-3 PUFAS TO STABILIZE OR IMPROVE APPETITE, FOOD INTAKE, LEAN BODY MASS AND BODY WEIGHT IN PATIENTS WITH CANCER WITH IMPROVEMENTS OBSERVED AT 2-2.2G PER DAY¹.



EPA and DHA PUFAs exert anti-inflammatory effects when incorporated into cellular membranes by decreasing the production of pro-inflammatory eicosanoids derived from arachidonic acid (AA) and by serving as the substrates for anti-inflammatory, proresolution lipid mediators such as resolvins and protectins. Adapted from Flock et al.¹².

THE EFFECT OF OMEGA-3 ENRICHED ONS IN PATIENTS WITH CANCER



In lung and oesphageal cancer patients, omega-3 PUFA enriched ONS is associated with reductions in CRP, TNF-α and PGE2¹³⁻¹⁶.



IMPROVES BODY WEIGHT & MUSCLE MASS^{14, 16-20}

In a meta-analysis comparing different nutritional interventions during chemo(radio)therapy, high-protein omega-3 PUFA-enriched ONS improved body weight compared with isocaloric controls (+1.89 kg, 95% CI 0.51-3.27, P=0.02)²⁰.

IMPROVES QUALITY OF LIFE^{14,19,21}

In advanced NSCLC patients, a 9-week intervention with omega-3 PUFA enriched ONS increased global health status (Δ +11.09; p = 0.02), and decreased fatigue and loss of appetite, compared to an isocaloric diet¹⁴.

IMPROVES TOLERANCE TO ANTI-CANCER TREATMENT^{14,17,19}

Head and neck cancer patients receiving omega-3 PUFA enriched ONS were less likely to require changes in scheduled anti-cancer treatment compared to patients receiving nutritional counselling alone (9.0% vs. 22.0%, p=0.029)¹⁹.



DESIGNED TO ADDRESS THE SPECIFIC NEEDS OF PATIENTS WITH CANCER

Introducing Fortimel OmegaCare

Per serving

✓ High protein (18 g) and high energy (306 kcal)

- Enriched with Omega-3 PUFAs (1.1 g EPA and 0.7g DHA)
- High in vitamin D (10 μg)
- Low volume (125 ml)
- Available in 2 sensory adapted flavours²²

*The European Society of Clinical Nutrition & Metabolism

References: 1. Arends et al. 2017 Clin Nutr, 36(1):11-48. 2. Fearon et al. 2011 Lancet Oncol, 12 (5):489-95. 3. Baracos et al. 2018 Nat Rev Dis Primers,4:17105. 4. Caro et al. 2007 Clin Nutr, 26(3):289-301. 5 Daly et al. 2016 Proc Nutri Soc, 77(2):1335-151. 6. Ryan et al. 2019 Nutrition, 67-68:110539. 7. Muscaritoli et al. 2017 Oncotarget, 8(45):79884-79896. 8. Cordeiro et al. 2020 Am J Hosp Palliat Care, 37(7):565-571. 9. Dolan et al. 2019 J Cachexia sarcopenia Muscle, 10(1):111-122. 10. Laird et al. 2016 J Clin Oncol, 34(23):2769-75. 11. Calder et al. 2013 Br J Clin Pharmacol, 75(3):645-62. 12. Flock et al. 2013 Diabetes Metab Res Rev, 29:431-445. 13. Guarcello et al. 2007 Nutritional Therapy Metabolism, 25(1):25-30. 14. Sanchez-Lara et al. 2014 Clin Nutr, 33(6):1017-1023. 15. Faber et al. 2015 Cachexia Sarcopenia and Muscle, 6(1):32-44. 16. Feijo et al. 2019 Nutrition, 61:125-131. 17. Aredes et al. 2019 Nutrition, 67-68:110528. 18. Van der meij et al. 2010 Hourtiton, 140(10):1774-1780. 19. Cereda et al. 2018 Radiotherapy & Oncology, 126, 81-88. 20. de van der Schueren et al. 2018 Ann Oncol, 29(5):1141-1153. 21. van der meij et al. 2012 Eur J Clin Nutr, 66(3):399-404. 22. Kwicien et al. 2023 Clin Nut ESPEN, 54 p500.



Fortimel OmegaCare* is a food for special medical purposes for the dietary management of patients with or at risk of disease related malnutrition due to cancer, chronic catabolic disease or cachexia. It must be used under medical supervision.

*Coming soon in new look & feel